Northera Review Shows Regulatory Challenges In Difficult Therapeutic Space
Executive Summary
Chelsea Therapeutics’ development program for droxidopa in neurogenic orthostatic hypotension led to discussion at a recent advisory committee meeting about the role of Special Protocol Assessments and appropriate validation of patient-reported outcome instruments.
You may also be interested in...
FDA’s Special Protocol Rescissions Get U.S. Capitol, Venture Capital Attention
House Appropriations Committee wants FDA to provide more justification when it changes a special protocol assessment.
Northera Survives Questions About Benefit Of Dizziness Endpoint At Advisory Panel
The Cardiovascular and Renal Drugs Advisory Committee Jan. 14 supported approval of the drug for symptomatic neurogenic orthostatic hypotension on a vote of 16-1.
FDA Makes It Formal, Rescinds SPA For Amarin’s ANCHOR Study
Agency makes clear that triglyceride levels are no longer an acceptable surrogate for reducing cardiovascular risk.